Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response.
about
B-Raf and the inhibitors: from bench to bedsidePutting the pieces together: How is the mitochondrial pathway of apoptosis regulated in cancer and chemotherapy?Regulation and function of TPL-2, an IκB kinase-regulated MAP kinase kinase kinaseApplication of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemiaComputational analyses of synergism in small molecular network motifsCase-specific potentiation of glioblastoma drugs by pterostilbeneCombinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.Continual low-level MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafishTargeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma.Quantifying factors for the success of stratified medicine.Dual-specificity MAP kinase phosphatases (MKPs): shaping the outcome of MAP kinase signalling.Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib.Are oncogenes sufficient to cause human cancer?Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanomaNext generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistanceRoles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance.Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing.Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches.Monitoring chemotherapeutic response by hyperpolarized 13C-fumarate MRS and diffusion MRI.ERK/pERK expression and B-raf mutations in colon adenocarcinomas: correlation with clinicopathological characteristics.GABAB receptor complex as a potential target for tumor therapyPrognostic value of RKIP and p-ERK in gastric cancerThe two faces of FBW7 in cancer drug resistance.Targeting the MAPK-RAS-RAF signaling pathway in cancer therapyMitogen-activated protein kinase signaling causes malignant melanoma cells to differentially alter extracellular matrix biosynthesis to promote cell survivalAtypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibitionA human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activitySystems-wide analysis of K-Ras, Cdc42, and PAK4 signaling by quantitative phosphoproteomics.OTX1 Contributes to Hepatocellular Carcinoma Progression by Regulation of ERK/MAPK Pathway.Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.[18 F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models.Quantitative implementation of the endogenous molecular-cellular network hypothesis in hepatocellular carcinoma.PLX4032: does it keep its promise for metastatic melanoma treatment?Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.Receptor tyrosine kinases and their activation in melanoma.Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.Cancer cells' epigenetic composition and predisposition to histone deacetylase inhibitor sensitization.The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?
P2860
Q21198860-E3740981-BB35-438F-BC5E-221F3BBFF43CQ28085240-71ADBC7F-3BBB-4971-AB72-FBFA6C7F1EC4Q28392677-AA482218-30CE-4220-BA83-9AE83DD75523Q28534259-26E95C36-C148-4495-93F7-6108FC7BE757Q28541174-E2E374F0-7F5C-4639-A622-D55FD779895AQ29048651-2B22DD22-98B9-4501-9917-1739AD094E87Q30277902-ECB784AB-8F6E-4712-971E-23A5AEA7414AQ34049618-A1483C20-4DE6-4C10-AD15-5FEFD1F95409Q34149419-7ECD74A8-5FF5-4179-9DC4-EF937A90E8B4Q34222257-D91A80A1-A4F2-40BC-AD1E-052E67A4E036Q34228544-296B684F-85F4-4FD6-9D59-C4477E3EFD09Q34289063-D61A491F-0C4E-462E-9309-375CD9F479C0Q34356841-CFBEB324-0D14-4F1E-B6FB-C096E7E8F25EQ34375732-7499B5AF-8D35-4CE6-BE20-BC5204676B81Q34497045-ACE544E3-BDD8-48CA-92BF-AB2264E2656CQ34669370-690CA316-446C-487A-9E9F-F30E6140720DQ34966603-832F910A-FCBE-4674-9515-C23217255544Q35237394-0E2C82F0-4D5B-45A8-BC99-D177F4A5A2EEQ35619558-BCBEFCDD-DC56-450A-86A2-0CF0D48E2E71Q35675442-44FF90E7-2118-4512-BA72-1F036DFBB3D5Q35703167-8C9B58DD-A0E6-41DC-8B07-25E639EBFDECQ35873526-BC4E6900-38EB-4504-89F7-55AD1C72C7DDQ35956277-B1AFF1D3-9264-4C04-BA76-FA1977BAFE92Q35956840-DA56FCEF-7E92-4B14-B2AF-B2FA9A8F93ECQ35999467-397295D1-648F-499C-9C91-96049AF2BAE0Q36278239-4CC8A198-A3C2-48BA-A819-F881AF0F6A50Q36654285-86A42939-D6FA-4560-B2BC-FBFC7D344353Q36822126-5D3FA495-0CE8-4430-B19F-9E4D28C85D70Q36844361-183F94F1-E7AB-4CCB-9A8F-FDFC5875C157Q37072842-3CF0EF94-F347-404E-88A4-7DE46A40C439Q37110450-F3D4860A-ED42-40CC-9853-3C7F9D62C3B3Q37119697-1DB583AB-17FE-4691-804F-C55D94A90F9AQ37359696-3C7EA1A0-6E78-47E5-A0AA-3BFF7055F6D0Q37718332-98647C19-9B93-452B-A304-8461B10E6111Q37799845-2539FF19-D6B3-44D9-9577-1B049C8ACF50Q37837732-6C0094CF-3BCA-4256-A85E-0449B57390D5Q37841746-D9AD88B4-7613-4748-BF6E-0E501E41F91DQ37865381-8CBAB3BF-B300-4465-A7FB-EB1BE4ECF3D8Q37899757-59B73124-AEC8-4D58-AC25-B4E04996543EQ37945533-89C678A1-DC24-491B-9868-195BE8D7494A
P2860
Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting the mitogen-activate ...... al feedback and drug response.
@en
Targeting the mitogen-activate ...... al feedback and drug response.
@nl
type
label
Targeting the mitogen-activate ...... al feedback and drug response.
@en
Targeting the mitogen-activate ...... al feedback and drug response.
@nl
prefLabel
Targeting the mitogen-activate ...... al feedback and drug response.
@en
Targeting the mitogen-activate ...... al feedback and drug response.
@nl
P2860
P1476
Targeting the mitogen-activate ...... al feedback and drug response.
@en
P2093
Christine A Pratilas
David B Solit
P2860
P304
P356
10.1158/1078-0432.CCR-09-3064
P407
P577
2010-05-14T00:00:00Z